全球In Silico药物发现市场：依技术平台、应用、最终用户、实施模式和治疗领域划分－2025年至2032年预测

预计到 2032 年，In Silico药物发现市场将成长至 58.5 亿美元，复合年增长率为 9.35%。

将电脑辅助药物发现的战略重要性定位为一项组织能力，该能力整合了资料科学、实验检验和营运管治。

In Silico药物发现正从一种辅助能力转变为现代转化研究的核心支柱，它融合了计算、数据和专业知识，加速药物发现生命週期中的决策。本文将该领域定位为不仅仅是一套工具；它是一种综合方法，可以缩短週期时间，提高假设质量，并在研发早期阶段做出更有把握的「继续/终止」决策。本文也展示如何将计算方法融入更广泛的研发策略中，使之与实验检验、监管要求和商业性需求保持一致不再是可选项，而是必要条件。

当今的格局呈现出多种相互作用的趋势：生物数据的指数级增长、分子科学专用机器学习方法的日益成熟，以及运算能力透过云端和本地环境的普及。这些因素共同作用，为团队创造了一个能够更有系统地探索化学空间、更精确地预测ADMET性质并从整合系统生物学的观点筛选靶点的环境。因此，领导者必须超越孤立的概念验证试点项目，着眼于建立可扩展的流程，使其具备可重复性、可解释性，并促进计算科学家、药物化学家和转化生物学家之间的跨职能协作。

此外，从供应商合作到联盟科研，协作经营模式的兴起使得规模较小的组织也能获得以往只有大型企业才能掌握的能力。这种能力获取方式的重新平衡凸显了编配能力的重要性——即协调资料来源、统一模型输出以及整合外部服务供应商的能力，从而在最大限度地加快创新速度的同时保护智慧财产权。摘要，这种趋势表明，In Silico药物发现如今已成为一项组织能力，需要对策略、管治、人员和基础设施进行投资才能持续创造价值。

计算方法、基础设施规模和伙伴关係模式的进步正在汇聚，从根本上重塑药物发现研究的搜寻策略和管治。

In Silico辅助药物发现领域正经历几项变革性的转变，这些转变正在改变成功的定义和实现方式。首先，调查方法的融合正在产生更可靠的结果。基于物理的分子模拟正越来越多地与机器学习模型相结合，这些模型能够从公共和专有资料集中学习，从而形成混合方法，既能捕捉机制层面的洞见，又能将预测扩展到大型化合物库。这种整合需要新的跨学科人才和工作流程，以协调不同来源的不确定性和检验标准。

其次，基础设施的成熟度提升了营运的扩充性。无论是本地丛集还是针对GPU工作负载最佳化的云端实例，高效能运算资源的取得都使得运算密集型模拟和快速推理流程的日常运作成为可能。因此，各组织正从孤立的演算法实验转向将预测模型持续整合到药物研发流程中，并辅以自动化资料管理和监控，以确保结果的可复现性。

第三，伙伴关係模式正在不断演变。技术供应商、受託研究机构(CRO) 和生物製药公司之间正在建立策略联盟，共用专业知识、在安全管治下共享精选资料共用并加速标靶检验。这些合作得到了专业服务供应商生态系统的补充，这些提供者提供模组化功能，例如从头分子设计引擎以及基于配体和结构的虚拟筛检平台，使用户能够建立客製化的工具链。

最后，监管和伦理方面的考量正成为技术采纳的核心要素。无论是内部管理机构或外部相关人员，对模型可解释性、资料来源和可复现性的期望都在不断提高。那些积极在其计算工作流程中建立审核和可解释性的公司，更有能力应对监管审查，并与临床和商业合作伙伴建立信任。这些变化通常并非渐进式的，而是正在重塑人才、技术和管治，使那些能够运作复杂混合运算策略的组织更具优势。

评估 2025 年美国实施的关税对电脑辅助药物发现操作中的采购、供应链韧性和采用决策的连锁反应。

2025年的政策环境，尤其是美国的关税，将对In Silico药物发现生态系统产生多方面的影响，而不仅限于直接采购成本。关税波动将影响关键硬体组件（例如GPU和专用加速器）的供应和价格，这些组件对于高通量分子模拟和深度学习模型训练至关重要。进口关税的上涨将延长采购週期，并改变资本预算决策，迫使各机构重新评估其运算基础设施的更新週期，并优先考虑工作负载整合和云端迁移，以降低前期投资风险。

除了硬体之外，关税也会影响全球软体和服务供应链。许多专业服务供应商和原始设备製造商 (OEM) 经营跨境製造和支援网络，而日益加剧的贸易摩擦使维护合约、备件物流和跨区域服务水平协议变得更加复杂。这些营运摩擦增加了本地部署系统的总拥有成本 (TCO)，促使企业转向在贸易协定更为有利且拥有本地资料中心的地区部署云端基础服务。

从策略角度来看，关税的不确定性将加速供应链多元化和区域化策略的推进。企业可能会寻求供应商冗余，与服务供应商和合约研究机构建立本地伙伴关係，或考虑投资关键零件的国内生产能力。虽然这些措施可能增强韧性，但也可能增加短期整合和检验的负担，因为团队需要适应不同的工具链和支援模式。此外，由于供应商会寻求透过服务商品搭售和变更授权条款来抵销利润压力，关税可能会间接影响人才流动和与供应商的谈判动态。

从专案角度来看，资费政策的影响凸显了弹性部署架构的重要性。结合云端爆发以应对高峰工作负载和本地平台处理敏感或延迟敏感任务的混合模式，既能应对成本波动，又能满足资料主权要求。因此，决策者应将资费政策方案纳入采购计画和弹性评估，以确保计算服务的连续性，同时谨慎管理资本支出和营运支出。

可操作的细分资讯：映射平台架构、应用程式需求、部署偏好、最终用户优先顺序和领域限制，以针对性地建立能力。

理解细分市场对于使技术投资和组织优先事项与不同工作流程和使用者的特定需求保持一致至关重要。基于技术平台，应专注于运算化学和生物资讯学与高效能运算、机器学习/人工智慧和分子建模各自扮演的不同角色。每个平台细分市场都需要专门的资料工程流程、检验框架和人才组合，而整合这些平台则为混合方法提供了可能，这些方法可以将基于机制的模拟与资料驱动的预测相结合。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 透过整合人工智慧驱动的生成模型和结构生物资讯学，加速先导化合物的最佳化筛选
• 利用量子计算演算法模拟酵素-配体相互作用（用于复杂标靶检验）
• 引入多体学资料融合平台用于药物反应表型的预测建模
• 部署云端原生高效能运算丛集以实现可扩展的分子动力学模拟
• 扩展我们的人工智慧药物发现平台，将主动学习融入新型骨架发现。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按技术平台In Silico药物发现市场

• 计算化学与生物资讯学
• 高效能运算
• 机器学习和人工智慧
• 分子建模

第九章 按应用划分In Silico药物发现市场

• ADMET预测
  • 吸收预测
  • 分布预测
  • 排泄预测
  • 代谢预测
  • 毒性预测
• 先导化合物的筛选与优化
  • 全新设计
  • 基于片段的最佳化
• 药物动力学模型
• 目标识别与检验
• 虚拟筛检
  • 基于配体的虚拟筛检
  • 基于结构的虚拟筛检

第十章In Silico药物发现市场

• 学术研究机构
• CRO（受託研究机构）
• 製药和生物技术公司

第十一章 按部署模式In Silico药物发现市场

• 云端基础的
• 本地部署

第十二章 按治疗领域In Silico药物发现市场

• 循环系统
• 中枢神经系统
• 感染疾病
• 肿瘤学

第十三章 区域性In Silico药物发现市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章In Silico药物发现市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国In Silico药物发现市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Dassault Systemes SE
  • Certara, Inc.
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • OpenEye Scientific Software, Inc.
  • Exscientia plc
  • Atomwise, Inc.
  • Insilico Medicine, Inc.
  • Cresset BioMolecular Discovery Ltd
  • Chemical Computing Group ULC

The In-Silico Drug Discovery Market is projected to grow by USD 5.85 billion at a CAGR of 9.35% by 2032.

Framing the strategic importance of computational drug discovery as an organizational competency that integrates data science, experimental validation, and operational governance

In-silico drug discovery is transitioning from a complementary capability to a central pillar of modern translational research, where computation, data, and domain expertise converge to accelerate decision-making across the discovery lifecycle. This introduction frames the discipline not merely as a set of tools but as an integrated approach that reduces cycle times, elevates hypothesis quality, and enables higher-confidence go/no-go decisions earlier in development. It also situates computational approaches within broader R&D strategies, where alignment with experimental validation, regulatory expectations, and commercial imperatives is increasingly mandatory rather than optional.

The contemporary landscape is characterized by multiple interacting forces: exponential growth in biological data, maturation of machine learning methods tailored to molecular science, and the commoditization of computational capacity through cloud and on-premise environments. These forces have produced an environment in which teams can explore chemical space more systematically, predict ADMET attributes with greater nuance, and triage targets through integrated systems biology perspectives. Consequently, leaders must think beyond isolated proof-of-concept pilots and toward scalable pipelines that embed reproducibility, explainability, and cross-functional handoffs between computational scientists, medicinal chemists, and translational biologists.

Furthermore, the rise of collaborative business models-ranging from vendor partnerships to consortium science-has enabled smaller organizations to access capabilities formerly exclusive to large pharmaceutical companies. This rebalancing of capability access places a premium on orchestration skills: the ability to coordinate data provenance, harmonize modeling outputs, and integrate external service providers in ways that preserve intellectual property while maximizing innovation velocity. In sum, the introduction underscores that in-silico drug discovery is now an organizational competency that requires strategy, governance, and investment in people and infrastructure to deliver sustained value.

How converging advances in computational methods, infrastructure scale, and partnership models are fundamentally reshaping discovery strategies and governance in drug research

The landscape of in-silico drug discovery is being reshaped by several transformative shifts that collectively change what success looks like and how it is achieved. First, methodological convergence is driving more robust outputs: physics-informed molecular simulation is increasingly combined with machine learning models that learn from both public and proprietary datasets, producing hybrid approaches that capture mechanistic insight while scaling predictions across large compound libraries. This convergence demands new interdisciplinary talent profiles and workflows that can reconcile different sources of uncertainty and validation criteria.

Second, infrastructure maturation is enabling operational scalability. Access to high-performance computing resources, whether on-premise clusters or cloud instances optimized for GPU workloads, permits the routine execution of computationally intensive simulations alongside rapid inference pipelines. As a result, organizations are shifting from isolated algorithmic experiments toward continuous integration of predictive models into discovery pipelines, with automated data curation and monitoring to ensure reproducibility.

Third, partnership models are evolving. Strategic alliances between technology vendors, contract research organizations, and biopharma companies are forming to pool domain knowledge, share curated datasets under secure governance, and accelerate target validation. These collaborations are complemented by an ecosystem of specialized service providers who offer modular capabilities-for example, de novo molecular design engines or ligand- and structure-based virtual screening platforms-enabling adopters to compose tailored toolchains.

Finally, regulatory and ethical considerations are becoming central to technology adoption. Expectations around model interpretability, data provenance, and reproducibility are increasing from both internal governance bodies and external stakeholders. Companies that proactively embed auditability and explainability into their computational workflows are better positioned to navigate regulatory scrutiny and build trust with clinical and commercial partners. Taken together, these shifts are not incremental; they reconfigure talent, technology, and governance in ways that favor organizations able to operationalize complex, hybrid computational strategies.

Evaluating how United States tariff measures enacted in 2025 cascade through procurement, supply chain resilience, and deployment decisions across computational drug discovery operations

The policy environment in 2025, including tariff actions originating from the United States, exerts multifaceted effects on in-silico drug discovery ecosystems that extend beyond immediate procurement costs. Tariff shifts influence the availability and pricing of critical hardware components such as GPUs and specialized accelerators, which are essential for high-throughput molecular simulation and deep learning model training. When import duties rise, procurement cycles elongate and capital budgeting decisions shift, prompting organizations to reevaluate refresh cadences for compute infrastructure and to prioritize workload consolidation or cloud migration to mitigate upfront capital exposure.

In addition to hardware considerations, tariffs affect the global software and service supply chain. Many specialized service providers and OEMs operate cross-border manufacturing and support networks; increased trade frictions complicate maintenance contracts, spare parts logistics, and multi-region service level agreements. These operational frictions can lead to higher total cost of ownership for on-premise systems and incentivize a rebalancing toward cloud-based deployments in jurisdictions with more favorable trade arrangements or local data center presence.

Strategically, tariff-driven uncertainty accelerates supply chain diversification and regionalization strategies. Organizations may pursue vendor redundancy, cultivate local partnerships with service providers and contract research organizations, or invest in domestic capacity for key components. Such moves can increase resilience but also raise near-term integration and validation burdens as teams adapt to heterogeneous toolchains and differing support models. Furthermore, tariffs can indirectly influence talent mobility and vendor negotiation dynamics, as suppliers seek to offset margin pressure through service bundling or altered licensing terms.

From a programmatic perspective, tariff impacts underscore the importance of flexible deployment architectures. Hybrid models that combine cloud bursting for peak workloads with on-premise platforms for sensitive or latency-dependent tasks enable teams to respond to both cost volatility and data sovereignty requirements. Decision-makers should therefore incorporate trade-policy scenarios into procurement planning and resilience assessments to ensure computational continuity while managing capital and operating expenditures prudently.

Actionable segmentation intelligence mapping platform architectures, application needs, deployment preferences, end-user priorities, and therapeutic area constraints for targeted capability building

Understanding segmentation is critical to aligning technical investments and organizational priorities with the specific demands of different workflows and users. Based on Technology Platform, attention should be paid to the distinct roles of Computational Chemistry and Bioinformatics versus High Performance Computing, Machine Learning and AI, and Molecular Modeling. Each platform segment requires tailored data engineering pipelines, validation frameworks, and talent mixes, and integrating these platforms creates opportunities for hybrid approaches that blend mechanistic simulation with data-driven prediction.

Based on Application, it is important to distinguish the varied requirements across ADMET Prediction, Lead Identification and Optimization, Pharmacokinetics Modeling, Target Identification and Validation, and Virtual Screening. ADMET Prediction itself decomposes into absorption prediction, distribution prediction, excretion prediction, metabolism prediction, and toxicity prediction, each demanding specialized datasets and domain-specific interpretability. Lead Identification and Optimization encompasses de novo design and fragment-based optimization approaches, which differ in their dependency on generative models versus expert-driven medicinal chemistry heuristics. Virtual Screening bifurcates into ligand-based virtual screening and structure-based virtual screening, with the former favoring cheminformatics and fingerprinting strategies and the latter relying on structural bioinformatics and docking accuracy.

Based on End User, differentiation among Academic and Research Institutes, Contract Research Organizations, and Pharmaceutical and Biotechnology Companies highlights divergent priorities: academic groups may prioritize methodological innovation and open science, contract research organizations emphasize reproducibility and throughput for client deliverables, and industry sponsors focus on regulatory robustness, IP protection, and integration with downstream clinical pipelines. Based on Deployment Model, the choice between Cloud Based and On Premise operations implicates governance, data residency, and cost structures, with hybrid approaches increasingly common to capture the benefits of both models.

Based on Therapeutic Area, the needs of cardiovascular, central nervous system, infectious diseases, and oncology programs vary in terms of target complexity, required assay validation, and tolerance for off-target liabilities. Oncology programs, for instance, often require sophisticated multi-omics integration and biomarker-driven validation, while infectious disease efforts may emphasize rapid screening and pathogen-specific constraint modeling. By mapping platform and application choices to end-user objectives and therapeutic constraints, organizations can more effectively prioritize investments and design fit-for-purpose workflows.

Regional capability patterns and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and partnership models

Regional context shapes how capabilities are adopted and scaled, influencing talent availability, regulatory expectations, and partnership ecosystems. In the Americas, there is a concentration of integrated biopharma organizations and a vibrant startup ecosystem that favors rapid prototyping, strong access to venture capital, and deep collaborations with clinical networks. These conditions support ambitious internal platforms and commercial partnerships, though they also require careful attention to IP strategy and compliance with evolving regulatory guidance.

In Europe, Middle East & Africa, the region presents a heterogeneous landscape where national research hubs and multinational centers of excellence coexist with growing public-private consortia. Regulatory harmonization efforts and strong emphasis on data protection influence preferred deployment models, often necessitating hybrid on-premise and cloud strategies that respect cross-border data transfer rules. Localized talent pools and strong academic links support method innovation, while strategic partnerships with contract research organizations help bridge scale and operational execution.

In the Asia-Pacific region, rapid expansion of computational capacity, strong government-backed initiatives, and a rising number of technology vendors are creating an environment conducive to large-scale adoption. This region often emphasizes cost-effective cloud solutions and regional data center investments, enabling high-throughput screening and model training at scale. However, differences in regulatory frameworks and language localization can introduce integration challenges, making regional partnerships and local compliance expertise critical for successful program deployment. Across all regions, organizations that align technical choices with local operational realities and partnership opportunities will achieve faster integration and greater resilience.

How differentiated technology capabilities, partnership models, and validation practices shape competitive positioning and long-term commercial relationships in computational discovery

Competitive dynamics in the in-silico drug discovery space are characterized less by single-vendor dominance and more by an ecosystem of specialized technology providers, platform integrators, and biopharma adopters forming modular value chains. Technology vendors differentiate through proprietary algorithms, curated training datasets, and the ability to integrate with laboratory automation and electronic laboratory notebook systems. Some firms emphasize physics-based simulation and molecular modeling, while others lead with generative chemistry and deep learning approaches, creating distinct value propositions for different stages of discovery.

Partnership archetypes include boutique technology providers collaborating with contract research organizations to offer end-to-end services, platform companies licensing core stacks to enterprise teams, and biopharma companies building internal centers of excellence that combine vendor solutions with in-house expertise. Strategic alliances between computational firms and large pharmaceutical organizations are common, and these relationships often center on co-development agreements, data-sharing frameworks, and joint validation studies that demonstrate translational relevance.

Additionally, service providers that can offer validated pipelines and regulatory-grade documentation gain preference among sponsors focused on clinical translation. The ability to demonstrate reproducibility, integrate with legacy IT systems, and meet stringent data governance requirements becomes a competitive differentiator. As a result, companies that invest in interoperability, transparent validation practices, and strong customer support tend to secure longer-term engagements and become preferred partners for enterprise-scale discovery initiatives.

Concrete strategic and operational priorities industry leaders must adopt to scale computational discovery from pilots to validated, production-grade drug discovery pipelines

Industry leaders should enact a coherent set of strategic and operational actions to convert computational promise into durable program outcomes. First, establish governance that ties computational objectives to therapeutic and portfolio goals, ensuring that model outputs feed directly into preclinical decision gates and that evaluation metrics are harmonized across teams. This alignment reduces friction when moving from pilot projects to production pipelines and clarifies investment priorities.

Second, invest in reproducibility and explainability. Embed version control for datasets and models, adopt standardized benchmarking protocols, and document workflows to support regulatory and audit requirements. These practices increase stakeholder confidence and reduce the risk of model drift or unintended biases affecting downstream experiments.

Third, architect flexible infrastructure. Adopt hybrid deployment patterns that allow for cloud elasticity during peak compute demands while preserving secure on-premise environments for sensitive data. Negotiate vendor contracts with clear service level agreements and redundancy provisions to mitigate supply chain disruptions and geopolitical risks.

Fourth, cultivate talent and cross-disciplinary collaboration. Build teams that combine computational scientists with medicinal chemists, pharmacologists, and regulatory experts to ensure that models are realistic, interpretable, and actionable. Provide continuous learning opportunities and create rotational programs that embed computational thinking across discovery functions.

Finally, pursue pragmatic partnerships and data strategies. Prioritize collaborations that provide curated, high-quality datasets with clear governance terms, and consider co-development agreements that share validation burdens. These steps accelerate time-to-impact while preserving strategic control over core IP and decision-critical datasets.

Transparent mixed-methods research protocol combining primary expert engagement, secondary literature synthesis, and multi-source data validation to ensure robust, actionable insights

The research approach underpinning this analysis combined qualitative expert engagement with structured secondary evidence synthesis and rigorous data validation protocols. Primary inputs were gathered through semi-structured interviews with domain experts spanning computational chemistry, machine learning, high-performance computing operations, and regulatory affairs, enabling direct insight into operational challenges, adoption barriers, and success factors observed in practice. These conversations were synthesized to surface common themes and divergent practices across organizational types.

Secondary evidence collection involved curated literature review of peer-reviewed methods papers, conference proceedings, technical white papers from technology providers, and publicly available regulatory guidance to triangulate claims and establish methodological baselines. Emphasis was placed on reproducibility and transparency, with methods and assumptions documented to permit independent review. Data validation employed cross-referencing across multiple independent sources, scenario testing to evaluate sensitivity to infrastructure and policy variables, and plausibility checks to ensure consistency with prevailing technology capabilities.

Limitations were acknowledged and addressed: primary interviews reflect experiential insights from a cross-section of organizations and are not exhaustive, and the pace of technological innovation means that specific tool capabilities evolve rapidly. To mitigate these constraints, the methodology prioritized durable patterns of behavior and structural dynamics over ephemeral product-level specifics. This mixed-methods design yields robust, actionable insights while making explicit the evidentiary basis for conclusions.

Consolidated conclusions emphasizing the necessity of governance, reproducibility, and deployment flexibility to realize sustained value from computational discovery programs

In conclusion, in-silico drug discovery is maturing into a strategic capability that requires deliberate organizational design, flexible infrastructure, and rigorous validation practices to deliver sustained translational value. The interplay of hybrid computational methods, evolving partnership models, and regional deployment realities creates both opportunities and operational complexities that leaders must navigate proactively. Those who align technical choices with therapeutic priorities, embed reproducibility and explainability into workflows, and pursue resilient procurement and deployment strategies will realize the greatest benefit.

Policy dynamics and supply chain pressures underscore the need for adaptable architectures and diversified vendor relationships, while segmentation-aware strategies ensure that investments map to the distinct needs of technology platforms, application types, end users, deployment models, and therapeutic areas. Ultimately, success depends on integrating computational insights into corporate decision-making processes and building cross-functional teams that can translate model outputs into decisive experimental actions. By treating in-silico discovery as a core competency rather than an auxiliary capability, organizations can accelerate the pathway from hypothesis to validated candidate while managing risk and preserving strategic optionality.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of AI-driven generative models with structural bioinformatics to accelerate hit-to-lead optimization
• 5.2. Adoption of quantum computing algorithms to simulate enzyme-ligand interactions for complex target validation
• 5.3. Implementation of multi-omics data fusion platforms for predictive modeling of drug response phenotypes
• 5.4. Deployment of cloud-native high-performance computing clusters for scalable molecular dynamics simulations
• 5.5. Expansion of AI-enabled de novo drug design platforms with active learning for novel scaffold discovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In-Silico Drug Discovery Market, by Technology Platform

• 8.1. Computational Chemistry And Bioinformatics
• 8.2. High Performance Computing
• 8.3. Machine Learning And Ai
• 8.4. Molecular Modeling

9. In-Silico Drug Discovery Market, by Application

• 9.1. Admet Prediction
  • 9.1.1. Absorption Prediction
  • 9.1.2. Distribution Prediction
  • 9.1.3. Excretion Prediction
  • 9.1.4. Metabolism Prediction
  • 9.1.5. Toxicity Prediction
• 9.2. Lead Identification And Optimization
  • 9.2.1. De Novo Design
  • 9.2.2. Fragment Based Optimization
• 9.3. Pharmacokinetics Modeling
• 9.4. Target Identification And Validation
• 9.5. Virtual Screening
  • 9.5.1. Ligand Based Virtual Screening
  • 9.5.2. Structure Based Virtual Screening

10. In-Silico Drug Discovery Market, by End User

• 10.1. Academic And Research Institutes
• 10.2. Contract Research Organizations
• 10.3. Pharmaceutical And Biotechnology Companies

11. In-Silico Drug Discovery Market, by Deployment Model

• 11.1. Cloud Based
• 11.2. On Premise

12. In-Silico Drug Discovery Market, by Therapeutic Area

• 12.1. Cardiovascular
• 12.2. Central Nervous System
• 12.3. Infectious Diseases
• 12.4. Oncology

13. In-Silico Drug Discovery Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. In-Silico Drug Discovery Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. In-Silico Drug Discovery Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Dassault Systemes SE
  • 16.3.2. Certara, Inc.
  • 16.3.3. Schrodinger, Inc.
  • 16.3.4. Simulations Plus, Inc.
  • 16.3.5. OpenEye Scientific Software, Inc.
  • 16.3.6. Exscientia plc
  • 16.3.7. Atomwise, Inc.
  • 16.3.8. Insilico Medicine, Inc.
  • 16.3.9. Cresset BioMolecular Discovery Ltd
  • 16.3.10. Chemical Computing Group ULC

LIST OF FIGURES

• FIGURE 1. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. IN-SILICO DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 187. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 203. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 206. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 207. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 208. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 216. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 221. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 224. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 225. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 226. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 227. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 228. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 229. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 230. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 231. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 232. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 233. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 236. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 237. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 238. LATIN AMERICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 275. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 278. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 279. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 280. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 281. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
• TABLE 282. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
• TABLE 283. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2024 (USD MILLION)
• TABLE 284. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2025-2032 (USD MILLION)
• TABLE 285. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2024 (USD MILLION)
• TABLE 286. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2025-2032 (USD MILLION)
• TABLE 287. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 288. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 289. MIDDLE EAST IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2024 (USD MILLION)

TABLE